AADI News and Press, Aadi Bioscience Inc. From 04/09/24

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for h...

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) PR Newswire Subgroup experienced efficacy and safety consistent with overall study population ...

2024-03-13 11:43:10 ET Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Conference Call March 13, 2024, 08:30 AM ET Company Participants Dave Lennon - President and CEO Scott Giacobello - CFO Loretta Itri - Chief Medical Officer Conference Call Participants ...

2024-03-13 08:02:01 ET More on Aadi Bioscience Aadi Bioscience: New Data Drives A Beaten Company Down, Not Really Justified Seeking Alpha’s Quant Rating on Aadi Bioscience Historical earnings data for Aadi Bioscience Read the full article on Seeking ...

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update PR Newswire FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively ...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

2024-03-12 10:50:24 ET More on Aadi Bioscience Aadi Bioscience: New Data Drives A Beaten Company Down, Not Really Justified Biggest stock movers today: Solar stocks, Intel, Scholastic and more. Aadi Bioscience stock plunges 57% on study data for anti-tumor drug ...

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES , March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a bio...

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 PR Newswire LOS ANGELES , March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on develo...

2024-03-04 06:43:57 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Aadi Bioscience, Inc. (NASDAQ: AADI ) announced, in late Friday trading, that it published the long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab -sirolimus...